NRX Pharmaceuticals (NRXP) Other Non-Current Liabilities (2021 - 2026)

NRX Pharmaceuticals (NRXP) has 5 years of Other Non-Current Liabilities data on file, last reported at $8.8 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 11.02% year-over-year to $8.8 million in Q1 2026; TTM through Mar 2026 was $8.8 million, a 11.02% decrease from a year earlier, with the FY2025 full-year figure at $12.3 million, up 118.19% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $8.8 million, down from $12.3 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for NRXP reached as high as $16.3 million in Q2 2025 and fell as low as $8000.0 in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged $7.8 million across 4 years, with a median of $8.8 million in 2026.
• Across the five-year window, Other Non-Current Liabilities soared 203225.0% in 2025 and decreased 11.02% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $17000.0 in 2023, then jumped by 33070.59% to $5.6 million in 2024, then surged by 118.19% to $12.3 million in 2025, then retreated by 28.75% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $8.8 million in Q1 2026, $12.3 million in Q4 2025, and $15.9 million in Q3 2025.